Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study

ConclusionsThese results demonstrate that pralatrexate may represent a promising treatment option for Chinese patients with R/R PTCL. The ORR of 52% compared favorably with prior studies of pralatrexate in other populations and there were no unanticipated side effects.Trial RegistrationClinicalTrials.gov identifier: NCT03349333.

http://link.springer.com/10.1007/s11523-019-00630-y

Source: Targeted Oncology - March 22, 2019 Category: Cancer & Oncology Source Type: research